Exagen Inc. (XGN)
$8.48+2.79%Close
BUYRECOVERY · day 51
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $205M
- Beta
- 2.12
- P/E (TTM)
- -10.34
- Short % float
- 5.10%
- Days to cover
- 2.5
- SI change
- -12.0%
- 1W
- +3.54%
- 1M
- +15.37%
- vs SPY 1W
- +3.68%
- vs SPY 1M
- +12.87%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 4
- VALUE
- 4
- GROWTH
- 26
- GARP
- 0
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-73.0%
REV YoY-
ROE-121.6%
EPS YoY-
ROA-36.4%
GROSS59
OP-19
NET-27
[VALUATION]
P/E TTM-10.34
P/E FWD-
SECTOR PE20.34
INDUSTRY PE31.41
P/B16.77
P/FCF-
EV/EBITDA-18.18
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E209.13
ALTMAN Z-
CURR RATIO3.18
ND/EBITDA-
BETA2.12
Company news
FAQ
- What is LOPJLB’s current signal on XGN?
- LOPJLB’s latest quantitative signal on Exagen Inc. (XGN) is BUY in a RECOVERY regime. Signals are updated daily.
- What market regime is XGN in?
- Exagen Inc. (XGN) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Exagen Inc. (XGN) do?
- Exagen Inc. develops and commercializes diagnostic testing solutions, leveraging its proprietary cell-bound complement activation products (CB-CAPs) technology under the AVISE brand throughout the United States. The company's mission is to equip rheumatologists with advanced tools for the precise diagnosis, prognosis, and ongoing management of autoimmune and related diseases, including systemic…